MAPK/ERK


The mitogen-activated protein kinase (MAPK) is a highly conserved family of serine/threonine kinases that mediate a board range of cellular processes, including proliferation, differentiation, motility, migration, stress response, apoptosis and survival. The activation of MAPK involves signaling pathways consisting of MAPK kinase (i.e. MAPKKK or MEKK) that activates MAPK/ERK (i.e. MAPKK or MEK). A variety of extracellular signals such as mitogens, cytokines, growth factors, and environmental stressors stimulate a phosphorylation-dependent increase in the activity of MAPK.
Activated MAPKs transduce the phosphorylation and activation of MAPK-activated protein kinases (MAPKAPKs), e.g. RSK, MSK, or MNK family, and MK2/3/5. There are three main MAPK families, signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 isoforms (p38α, β, γ, and δ). ERK signaling is involved in cell division, migration and survival. p38 MAPK and JNK/SAPK pathways are activated by cellular stress. The p38 MAPK pathway regulates cell motility, transcription, and chromatin remodeling. JNK/SAPK signaling affects apoptosis and inflammation. Dysregulation of MAPK pathway results in tumorgenesis and other pathological conditions.
-
B7784 AL 8697Target: p38Summary: p38α inhibitor,potent and selective -
B7791 6-Bnz-cAMP sodium saltSummary: cAMP analog,PKA activator -
A9501 OTS514Summary: TOPK inhibitor,highly potent -
A9502 OTS964 hydrochlorideSummary: TOPK inhibitor,potent and selective -
B4886 DTP3 TFASummary: inhibitor of GADD45β/MKK7 complex -
B2190 H 89 2HCl3 CitationSummary: Potent PKA inhibitor -
B1831 Sertaconazole nitrateSummary: Broad-spectrum antifungal -
BA2003 U0126Summary: A potent, non-ATP-competitive, selective MEK inhibitor -
C5850 SD 169Summary: selective ATP competitive inhibitor of the MAP kinases p38α and p38β -
A8780 WM-2474Summary: Inactive analogue of WM-8014, used as control compound

